Daftar Login

[PDF] MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody,

MEREK : mbs303

[PDF] MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody,

mbs303MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. TheMBS-303: a CD20 inhibitors, CD3 stimulants Drug, Initially developed by Beijing Mabworks Biotech Co., Ltd.,

IDR 10.000
IDR 100.000 Disc -90%
Kuantitas